Re: positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial.

Abstract

available at http://jurology.com/ Editorial Comment: After a previous phase I study this is the first phase III study testing the diagnostic accuracy of iodine-124 girentuximab positron emission tomography/computerized tomography (CT) in the detection of clear cell (cc) renal cell carcinoma (RCC). The new test uses the chimeric antibody G250 that binds to carbonic anhydrase IX, a cell surface antigen highly expressed in most ccRCC but not in other RCC subtypes. The study is methodologically correct comparing the new test to the standard radiological test (contrast enhanced CT) and to tumor pathology, in this case represented by the surgical specimen. The latter, instead of being a limitation as indicated by the authors, is one of the strongest methodological points of the study. The sample size, corrected after interim analysis, is sufficient to reach statistical significance. Iodine-124 girentuximab positron emission tomography/CT consistently outperformed contrast enhanced CT in sensitivity and specificity in large and small renal masses. How useful the test will be in real practice in patients with large renal masses is uncertain except for systemic treatment purposes. However, there is a large window of opportunity for this test in the diagnostic and treatment decision process for small renal masses. The 2 important concepts to be retained are 1) the test allows identification of ccRCC, the most aggressive of the subtypes, and 2) it is quite accurate in identifying small ccRCC. M. Pilar Laguna, M.D., Ph.D. Re: Clinical and Pathologic Impact of Select Chromatin-Modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma A. A. Hakimi, Y. B. Chen, J. Wren, M. Gonen, O. Abdel-Wahab, A. Heguy, H. Liu, S. Takeda, S. K. Tickoo, V. E. Reuter, M. H. Voss, R. J. Motzer, J. A. Coleman, E. H. Cheng, P. Russo and J. J. Hsieh Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York Eur Urol 2013; 63: 848–854. Abstract available at http://jurology.com/ Editorial Comment: The authors of this elegant study describe the frequency of mutations of 4 chromatin modulating tumor suppressors in clear cell (cc) renal cell carcinoma (RCC). Besidesavailable at http://jurology.com/ Editorial Comment: The authors of this elegant study describe the frequency of mutations of 4 chromatin modulating tumor suppressors in clear cell (cc) renal cell carcinoma (RCC). Besides 0022-5347/13/1902-0493/0 http://dx.doi.org/10.1016/j.juro.2013.04.067 THE JOURNAL OF UROLOGY Vol. 190, 493-495, August 2013 © 2013 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC. Printed in U.S.A. www.jurology.com 493

DOI: 10.1016/j.juro.2013.04.067

Cite this paper

@article{Laguna2013RePE, title={Re: positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial.}, author={M Pilar Laguna}, journal={The Journal of urology}, year={2013}, volume={190 2}, pages={493} }